A First-in-Human, Randomized, Double-blind, Placebo-controlled Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STR-324 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs STR-324 (Primary)
- Indications Pain
- Focus Adverse reactions; First in man
- Sponsors Stragen France SAS
- 11 Dec 2018 Status changed from recruiting to completed.
- 23 Feb 2018 Status changed from not yet recruiting to recruiting.
- 19 Feb 2018 New trial record